SGO Annual Meeting on Women's Cancer

Adding Keytruda to chemotherapy improved survival outcomes in patients with endometrial cancer, regardless of their mismatch repair or PD-L1 status.

A phase 3 trial determined that Tivdak showed “game-changing results” for certain patients with cervical cancer, an expert told CURE®.

Cryocompression was found to be tolerable and effective in preventing chemotherapy-induced peripheral neuropathy in a small study.

Patients with ovarian cancer who utilized palliative care tended to have fewer hospital readmissions than those who did not, according to a recent study.

There were no major differences in survival when comparing intravenous and intraperitoneal chemotherapy plus Avastin in patients with advanced ovarian cancer, research shows.

“These results position mirvetuximab soravtansine to become a practice-changing, biomarker-driven, standard-of-care treatment option for patients with (high folate receptor-alpha)-positive, platinum-resistant ovarian cancer,” noted one of the study authors.

Zejula plus Avastin led to promising progression-free survival rates with no new side effects for patients with newly diagnosed, advanced ovarian cancer.

Jaron Mark, M.D., a gynecologic oncology fellow at Roswell Park Comprehensive Cancer Center, discusses the opioid crisis, and the steps that his institution is taking to combat potential addiction in women who undergo surgery for gynecologic cancer.

PARP inhibitors are generating a lot of excitement in the field of ovarian cancer. But how, exactly, do they work? CURE spoke with one expert to find out.

Knowing which kind of therapy works best can help in determining the ideal cancer care for patients.

“There has been a rapid expansion in the use of checkpoint inhibition in many solid tumor types,” lead author Emily Hinchcliff, M.D.

At the inaugural Ovarian Cancer Heroes gala, held in New Orleans ahead of the 49th Society of Gynecologic Oncology Annual Meeting on Women’s Cancers, four individuals — a physician, nurse navigator and two patient-turned-advocates — were awarded for the contributions they have made to increase awareness and advance research and education for ovarian cancer.

Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.

Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.

Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

PARP inhibitors like niraparib are bringing big change to the treatment of ovarian cancer, says Kathleen N. Moore, M.D.

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

The PARP inhibitor niraparib proved to be effective in improving progression-free survival in recurrent ovarian cancer, according to a recent study.

Concern about vaccine safety and perceived lack of necessity remain the main reasons parents give for not having their teenage daughter vaccinated against HPV.

Jubilee Brown, M.D., answers some common questions about genetic counseling in patients with ovarian cancer.

Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.

Elizabeth Swisher, M.D., discusses the ARIEL2 study, which proved that rucaparib may be a promising agent for patients with recurrent ovarian cancer.

Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.